AzTrials
AzTrials

Type 2 Diabetes Mellitus in ObeseCGM-BARIANCT04332354

Glycemic Profile by CGMS in Diabetic Patients After Bariatric Surgery

An observational study of Type 2 Diabetes Mellitus in Obese and Bariatric Surgery Candidate, run by University Hospital, Caen.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this observational prospective monocentric study is to examine glycemic patterns in adult T2D patients candidates to bariatric surgery, by using a continuous glucose monitoring (CGM) sensor over 14 days post-surgery, in order to search for indicators predicting T2D remission 1 year after surgery. Read more about this study

Who is it for?
Ages 18 years and older
How many people
31 participants
Where
No sites listed yet
Study dates
30 Mar 2016to 30 May 2018
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: T2D, obesity (BMI>35), candidates for metabolic surgery oral or injectable anti diabetic treatments including insulin injections or pump therapy

Who may be able to join

  • type 2 diabetes and obesity (BMI> 35)
  • treated with oral anti-diabetic medication and/or insulin therapy
  • candidate for bariatric surgery

Who cannot join

  • refusal of CGM recordings
  • refusal of bariatric surgery

About this study

Official title: Evaluation by CGMS (Continuous Glucose Monitoring System) of the Evolution of the Glycemic Profile in Diabetic Patients in Immediate Post-operative Bariatric Surgery: An Observational Study in Routine Care

The aim of this observational prospective monocentric study is to examine glycemic patterns in adult T2D patients candidates to bariatric surgery, by using a continuous glucose monitoring (CGM) sensor over 14 days post-surgery, in order to search for indicators predicting T2D remission 1 year after surgery.

Read the detailed description

In this exploratory monocentric study performed at the Caen University Hospital in France, adult T2D patients consecutively enrolled for metabolic surgery will be prospectively included for continuous glucose monitoring (CGM) recordings during the month preceding bariatric surgery and during the 2 weeks following surgery. Changes in body weight will be evaluated using weight measurement, BMI measurement and the percentage of excess weight loss (% EWL), calculated using the formula: initial weight-actual weight/initial weight - (25 x height2). Changes in diabetic status will be evaluated by HbA1c assay and collection of data on anti-diabetic treatment maintained during the follow-up. The Ad-Diarem score for predicting diabetes remission will be calculated in each patient from several variables including age, diabetes duration, insulin use, other glucose-lowering agents used, number of glucose-lowering agents used and HbA1c level. The variables recorded by CGM will include : mean daily interstitial glucose concentration (mg/dL), standard deviation (SD) of glucose concentration (mg/dL), coefficient of variation (CV) of glucose concentration corresponding to the SD-to-mean daily interstitial glucose ratio, time in normoglycemia (ie in the stringent 70-140mg/dL target which better reflects normoglycemia than the 70-180 mg/dl target) or time in range (TIR) as a percentage over 24h, time spent in hyperglycemia (ie >140mg/dL) or time above range (TAR) as a percentage over 24h, and time spent in hypoglycemia (<70mg/dL) or time below range (TBR) as a percentage over 24h.

Judgement criteria are defined as follows: the success of bariatric surgery will be defined as a % EWL >50%; normalization of glycemia will be defined as a mean 24-hr interstitial glucose level <100mg/d during the CGM recording period; diabetes remission after metabolic surgery will be defined as an HbA1c level at 1 year after surgery of < 6.0% without the use of any glucose-lowering agent. Such thresholds were chosen to meet the definition of complete remission by the American Society for Metabolic and Bariatric Surgery and the American Diabetes Association.

Quantitative variables will be expressed as mean + standard deviation. Qualitative variables will be expressed as percentages. Differences in quantitative variables, when compared to the pre-operative period, will be examined using Students t-test for paired data or with ANOVA. Analysis of subgroups will be carried out using Chi-2 test. Identification of predictive factors for diabetes remission will be based on analysis of ROC curves and the calculation of area under the curve data, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive and negative likelihood ratio (LR+ and LR-) at different thresholds for each study variable including the pre-operative and post-operative CGM variables and the Add-Diarem score.

Being tested
routine care. No intervention
Keywords
continuous glucose monitoring

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • routine care. No interventionOther

    no intervention

Study groups in NCT04332354
Study groupRoleWhat they receive
T2D diabetes obese subjectsPatients have T2D diabetes and are candidates for bariatric surgery. They will receive routine cares and follow-up and will have CGM measurement before and 2 weeks following the surgery
Receives: Other: routine care. No intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. glycemic profile after bariatric surgery

    CGM recordings 4-14 days of the immediate postoperative period

    Measured: 4-14 days recordings

Secondary outcomes (2)
  1. glycemic profile before bariatric surgery

    CGM recordings before bariatric surgery

    Measured: 5 days recordings

  2. identification of predictive factors for diabetes remission 1 year after surgery

    CGM variables and Add-Diarem score

    Measured: 5 days recordings for CGM

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Apr 2020
  2. Study start30 Mar 2016
  3. Primary completion30 Mar 2018
  4. Study completion30 May 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
31 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04332354
Sponsor's protocol ID
CHU 20-501
Acronym
CGM-BARIA
Status last verified
Mar 2020
First submitted
31 Mar 2020
Last updated
2 Apr 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Type 2 Diabetes Mellitus in Obese and Bariatric Surgery Candidate, run by University Hospital, Caen.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

glycemic profile after bariatric surgery (time frame: 4-14 days recordings). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in